


## What You Didn't Know About Advanced Basal Cell Carcinoma (BCC)



BCC is the most common type of non-melanoma skin cancer in the USA, Europe & Australia Australia

It is estimated that about 100 million people worldwide are diagnosed with BCC every year\*

Primarily caused by exposure to sunlight<sup>5</sup>

with relatively simple procedures or treatments But around 1%


The good news is most cases


can be cured

of patients with **BCC** develop a more advanced form of the disease<sup>5</sup>

This can be

disfiguring





or other parts


of the body

person differently, and there is

(metastatic)<sup>5,7</sup>


Advanced BCC impacts each

locally advanced



still significant unmet need around the world

Ongoing investigation into treatments is creating



References:

new possibilities

for people with advanced

**BCC** now and in the future

- N.R.Telfer, G.B.Colver and C.A.Morton. Guidelines for the management of basal cell carcinoma.
   The British Journal of Dermatology. 2008;158(7):35-48.

   Von Hoff et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. New Engl J Med.
- 2009;361:1164-1172.

  3. Gilbody JS, et al. What causes basal cell carcinoma to be the commonest cancer? Aust J Public
- Health.1994; 18(2):218-21.

  4. Lucas R, McMichael T, Smith W, Armstrong B. Solar ultraviolet radiation: global burden of disease from solar
- ultraviolet radiation. Geneva: WHO, 2006. Available at: http://www.who.int/uv/health/solaruvradfull\_180706.pdf.

  5. Walling HW, Fosko SW, Geraminejad PA, Whitaker DC, Arpey CJ. Cancer Metastasis Rev. 2004;23:389-402.
- 6. Tang JY, Epstein EH. Medical Management of Advanced or Metastatic Basal Cell Carcinomas. AccessMedicine. 2010.
   Available at: http://www.medscape.com/viewarticle/720380 Last accessed 10 June 2013.

   7. Joshi AD, Forsyth MT, Fryefield DC, et al.Demographic and treatment characteristics for advanced basal cell

carcinoma (aBCC) in an oncology outpatient setting. J Clin Oncol 2011;29(15, Suppl): abstract e19001.

All information must be approved by local legal and regulatory teams prior to use with external audiences and all applicable SOPs must be followed.